Published in Leukemia on April 01, 2004
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell (2015) 1.74
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res (2014) 1.69
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res (2011) 1.62
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood (2005) 1.57
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood (2015) 1.52
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther (2008) 1.47
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Replicative potential of human natural killer cells. Br J Haematol (2009) 1.19
Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol (2015) 1.18
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 1.15
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther (2009) 1.12
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood (2008) 1.10
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
CD19-CAR trials. Cancer J (2014) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res (2014) 1.08
Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther (2014) 1.07
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest (2016) 1.05
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology (2015) 1.04
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res (2014) 1.03
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res (2010) 1.02
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther (2013) 1.00
Are natural killer cells superior CAR drivers? Oncoimmunology (2014) 0.99
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med (2010) 0.99
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity (2016) 0.96
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
An efficient low cost method for gene transfer to T lymphocytes. PLoS One (2013) 0.95
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res (2013) 0.94
Engineering CAR-T cells: Design concepts. Trends Immunol (2015) 0.93
Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 0.91
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 0.90
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin Exp Immunol (2006) 0.88
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica (2012) 0.88
The past, present, and future of adoptive T cell therapy. Immune Netw (2012) 0.86
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86
CAR-T Cell Therapy for Lymphoma. Annu Rev Med (2015) 0.86
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer (2013) 0.85
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol (2016) 0.84
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Mol Ther (2011) 0.84
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
CD133, Selectively Targeting the Root of Cancer. Toxins (Basel) (2016) 0.83
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget (2015) 0.83
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther (2015) 0.83
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia (2015) 0.82
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica (2016) 0.82
Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia (2014) 0.82
Immunotherapy in acute leukemia. Semin Hematol (2009) 0.82
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther (2015) 0.82
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget (2015) 0.82
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology (2015) 0.81
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther (2016) 0.81
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol (2016) 0.81
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica (2014) 0.80
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors. PLoS One (2015) 0.79
Stem cell in alternative treatments for brain tumors: potential for gene delivery. Mol Cell Ther (2014) 0.79
Chimeric antigen receptors (CARs) from bench-to-bedside. Immunol Lett (2013) 0.79
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Structural basis of presequence recognition by the mitochondrial protein import receptor Tom20. Cell (2000) 2.84
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. J Cell Biol (2000) 2.16
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med (1996) 2.10
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1. J Biol Chem (2001) 1.95
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Functions of signal and signal-anchor sequences are determined by the balance between the hydrophobic segment and the N-terminal charge. Proc Natl Acad Sci U S A (1992) 1.72
Molecular cloning and sequencing of cDNA for yeast porin, an outer mitochondrial membrane protein: a search for targeting signal in the primary structure. EMBO J (1985) 1.67
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
An essential role for BLNK in human B cell development. Science (1999) 1.64
Molten globule of cytochrome c studied by small angle X-ray scattering. J Mol Biol (1993) 1.63
In vitro synthesis and integration into mitochondria of porin, a major protein of the outer mitochondrial membrane of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1982) 1.62
A short amino-terminal segment of microsomal cytochrome P-450 functions both as an insertion signal and as a stop-transfer sequence. EMBO J (1987) 1.61
A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. Leuk Res (1985) 1.61
Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation (1998) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med (1998) 1.55
PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol (1995) 1.51
Systematic analysis of stop-transfer sequence for microsomal membrane. J Biol Chem (1991) 1.50
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ (2006) 1.47
The four cytoplasmically made subunits of yeast mitochondrial cytochrome c oxidase are synthesized individually and not as a polyprotein. Proc Natl Acad Sci U S A (1980) 1.46
Reconstitution of the initial steps of mitochondrial protein import. Nature (1995) 1.44
A mitochondrial import factor purified from rat liver cytosol is an ATP-dependent conformational modulator for precursor proteins. EMBO J (1993) 1.42
Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood (1992) 1.42
Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol (1985) 1.41
Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol (2005) 1.41
PAMELA measurements of cosmic-ray proton and helium spectra. Science (2011) 1.39
"Cytoplasmic" expression of nuclear antigens. Leukemia (1989) 1.38
Reconstitution of hepatic microsomal stearoyl-coenzyme A desaturase system from solubilized components. J Biochem (1972) 1.37
Treatment of pyogenic granuloma with a sclerosing agent. Dermatol Surg (2001) 1.37
Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood (1995) 1.36
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood (1998) 1.33
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia (2009) 1.33
Metaxin is a component of a preprotein import complex in the outer membrane of the mammalian mitochondrion. J Biol Chem (1997) 1.32
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest (1999) 1.32
Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol (2007) 1.31
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest (1985) 1.30
Trehalose levels and survival ratio of freeze-tolerant versus freeze-sensitive yeasts. Appl Environ Microbiol (1990) 1.30
Interaction of mitochondrial targeting signals with acidic receptor domains along the protein import pathway: evidence for the 'acid chain' hypothesis. EMBO J (1998) 1.30
Characterization of rat TOM40, a central component of the preprotein translocase of the mitochondrial outer membrane. J Biol Chem (2000) 1.27
Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem (1993) 1.25
Forced transmembrane orientation of hydrophilic polypeptide segments in multispanning membrane proteins. Mol Cell (1998) 1.25
Expression of T-cell receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human intestinal mucosa. Immunology (1989) 1.24
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 1.24
Signal recognition particle is required for co-translational insertion of cytochrome P-450 into microsomal membranes. Proc Natl Acad Sci U S A (1984) 1.22
Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion (2002) 1.22
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia (2004) 1.21
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med (1993) 1.20
The amino-terminal structures that determine topological orientation of cytochrome P-450 in microsomal membrane. EMBO J (1990) 1.19
Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens (2011) 1.18
Urinary oligosaccharides of mannosidosis. J Biol Chem (1980) 1.18
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia (2003) 1.18
MSF, a novel cytoplasmic chaperone which functions in precursor targeting to mitochondria. EMBO J (1994) 1.18
A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer (1998) 1.18
Mitochondrial porin can be translocated across both endoplasmic reticulum and mitochondrial membranes. J Biochem (1992) 1.17
Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res (1998) 1.17
Binding of mitochondrial precursor proteins to the cytoplasmic domains of the import receptors Tom70 and Tom20 is determined by cytoplasmic chaperones. EMBO J (1997) 1.17
Identification of early plasma cells in peripheral blood and their clinical significance. Br J Haematol (1996) 1.16
Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia (2005) 1.15
Assessment of topogenic functions of anticipated transmembrane segments of human band 3. J Biol Chem (1998) 1.15
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood (1994) 1.14
Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest (1996) 1.14
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol (1996) 1.14
Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. Br J Pharmacol (2014) 1.13
cDNA cloning and characterization of mitochondrial import stimulation factor (MSF) purified from rat liver cytosol. J Biochem (1994) 1.13
Membrane topogenesis of a type I signal-anchor protein, mouse synaptotagmin II, on the endoplasmic reticulum. J Cell Biol (2000) 1.12
Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia (2003) 1.11
Cytoplasmic chaperones determine the targeting pathway of precursor proteins to mitochondria. EMBO J (1996) 1.11
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia (2012) 1.10
X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol Rev (1994) 1.09
Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia (2007) 1.08
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia (2011) 1.08
Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy (2003) 1.08
Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol (1981) 1.08
The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J Immunol (1987) 1.07
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia (2009) 1.07
An anomalous positron abundance in cosmic rays with energies 1.5-100 GeV. Nature (2009) 1.07
Identification of the protein import components of the rat mitochondrial inner membrane, rTIM17, rTIM23, and rTIM44. J Biochem (1998) 1.05
Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J Clin Invest (1994) 1.05
Analysis of the functional domain of the rat liver mitochondrial import receptor Tom20. J Biol Chem (1997) 1.05
Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood (2001) 1.05